Cost-effectiveness of durvalumab with or without Olaparib as a first-line treatment for dMMR type of advanced/recurrent endometrial cancer

Puntos clave

• Durvalumab combined with olaparib increases survival rates in advanced dMMR endometrial cancer patients compared to chemotherapy alone.
• The cost-effectiveness analysis focuses on patients with advanced/recurrent dMMR endometrial cancer, emphasizing financial implications.
• Phase III DUO-E trial findings indicate significant improvements in survival outcomes, supporting the use of durvalumab.
• Results suggest that durvalumab in combination therapy may be a viable option, but cost considerations must be addressed.